Skip to main content
DFTX
NASDAQ Life Sciences

Definium Therapeutics Updates on Phase 3 Milestones and Strong Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$20.7
Mkt Cap
$2.234B
52W Low
$6.345
52W High
$26.25
52W Position info
226% above low
Off High info
21% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

DFTX has more than doubled off its 52-week low of $6.345.

Summary

Definium Therapeutics released an updated corporate presentation detailing upcoming Phase 3 data readouts for its DT120 ODT program, pipeline advancements, and a strong financial position with cash runway into 2028.


Key Events · Product Development and Regulatory · DFTX

  • Upcoming Phase 3 Data Readouts

    Three Phase 3 topline data readouts for DT120 ODT are anticipated in late Q2 2026 (Emerge for MDD), early Q3 2026 (Voyage for GAD), and late Q3 2026 (Panorama for GAD).

  • Pipeline Advancement

    The Ascend Phase 3 study for DT120 ODT in MDD has been initiated in Q2 2026, and initial data for DT402 in Autism Spectrum Disorder (ASD) is expected in 2026.

  • Strong Financial Position

    The company reported $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, with a projected cash runway extending into 2028.

  • Positive Phase 2b Results

    DT120 ODT demonstrated statistically and clinically significant improvements in anxiety and depression symptoms in Phase 2b, with a favorable tolerability profile.


Analysis · DFTX · Life Sciences

This corporate presentation provides a comprehensive update on Definium Therapeutics' clinical pipeline, highlighting multiple near-term Phase 3 data readouts for its lead candidate, DT120 ODT, in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The confirmation of a strong cash position extending into 2028 provides financial stability as these critical milestones approach. Positive Phase 2b data underpins confidence in the ongoing Phase 3 program, and the outlined commercial strategy points to a substantial market opportunity.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DFTX was trading at $20.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $6.35 to $26.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DFTX - Latest Insights

DFTX
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $30.15 info
Change: -$5.85 (-16%) info
Market Cap: $4.129B info
DFTX
Nov 09, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $35.36
Real-time Price: $30.15 info
Change: -$5.20 (-15%) info
Market Cap: $4.129B info
DFTX
Sep 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $30.15 info
Change: -$14.85 (-33%) info
Market Cap: $4.129B info
DFTX
Sep 14, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.46
Real-time Price: $30.15 info
Change: -$11.31 (-27%) info
Market Cap: $4.129B info
DFTX
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.39
Real-time Price: $30.15 info
Change: -$9.24 (-23%) info
Market Cap: $4.129B info